The abstract is read at the publisher; the summary is JClub's.
CKM stage 3-4 in MASLD is linked to the highest baseline prevalence of advanced liver fibrosis, at 31.6%, compared with 9.6% in CKM stage 0-1.
- Why it matters: CKM syndrome has not been well characterized in MASLD, leaving uncertainty about how combined cardiovascular, kidney, and metabolic dysfunction relates to fibrosis severity and clinical liver outcomes.
- What they did: In 12,097 MASLD patients from the VCTE-Prognosis cohort, CKM stages were used to model advanced fibrosis (LSM ≥10 kPa), liver stiffness progression (≥20% increase and Baveno upshift), and incident liver-related events.
- The result: Over 4.5 years, CKM stage 2 and 3-4 predicted higher liver stiffness progression (adjusted HR 1.321 and 1.767), while only CKM stage 3-4 increased LRE risk (adjusted HR 1.975).
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.